CRISPR Therapeutics AG (NASDAQ:CRSP) Given Consensus Recommendation of “Moderate Buy” by Brokerages

CRISPR Therapeutics AG (NASDAQ:CRSP) has earned a consensus rating of “Moderate Buy” from the seventeen analysts that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, six have assigned a hold rating, nine have issued a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $67.9412.

A number of research firms have commented on CRSP. Citigroup restated a “market outperform” rating on shares of CRISPR Therapeutics in a research report on Tuesday, August 25th. Weiss Ratings reiterated a “sell (d-)” rating on shares of CRISPR Therapeutics in a report on Friday, July 17th. UBS Group set a $80.00 target price on shares of CRISPR Therapeutics in a research report on Friday, June 12th. Needham & Company LLC reiterated a “buy” rating and set a $82.00 price target on shares of CRISPR Therapeutics in a research report on Monday, August 31st. Finally, HC Wainwright reissued a “buy” rating on shares of CRISPR Therapeutics in a research note on Monday, August 31st.

CRISPR Therapeutics Trading Down 1.3%

Shares of CRSP stock opened at $56.56 on Monday. The company has a current ratio of 17.85, a quick ratio of 17.85 and a debt-to-equity ratio of 0.34. CRISPR Therapeutics has a twelve month low of $44.12 and a twelve month high of $78.48. The company’s 50-day moving average price is $53.08 and its 200-day moving average price is $52.83. The stock has a market cap of $5.47 billion, a price-to-earnings ratio of -11.88 and a beta of 1.76.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings data on Tuesday, June 30th. The company reported ($0.94) earnings per share (EPS) for the quarter. CRISPR Therapeutics had a negative return on equity of 24.39% and a negative net margin of 3,368.72%.The firm had revenue of $10.18 million for the quarter. As a group, equities analysts predict that CRISPR Therapeutics will post -4.47 earnings per share for the current year.

Institutional Trading of CRISPR Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Engineers Gate Manager LP acquired a new stake in shares of CRISPR Therapeutics in the second quarter valued at $585,000. NewEdge Advisors LLC boosted its holdings in CRISPR Therapeutics by 131.3% during the 2nd quarter. NewEdge Advisors LLC now owns 8,217 shares of the company’s stock valued at $448,000 after acquiring an additional 4,664 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in CRISPR Therapeutics in the 2nd quarter valued at about $970,000. Ameritas Advisory Services LLC acquired a new position in CRISPR Therapeutics in the 2nd quarter valued at about $56,000. Finally, HB Wealth Management LLC purchased a new stake in CRISPR Therapeutics during the second quarter worth about $289,000. Hedge funds and other institutional investors own 69.20% of the company’s stock.

About CRISPR Therapeutics

CRISPR Therapeutics AG (NASDAQ: CRSP) is a biotechnology company focused on developing gene-editing medicines using CRISPR/Cas9 technology. The company’s programs are designed to modify disease-associated genes in human cells, with the goal of treating serious conditions across hematology, oncology, autoimmune disease and regenerative medicine.

Its most advanced product is Casgevy (exa-cel), an autologous cell therapy developed in collaboration with Vertex Pharmaceuticals. Casgevy uses CRISPR/Cas9 gene editing to modify a patient’s blood stem cells and is approved in several markets for eligible patients with sickle cell disease and transfusion-dependent beta thalassemia.